Editorial: Angiogenesis blockade for the treatment of gastrointestinal cancer

Frontiers in Oncology

Oncology

Yulong He¹  Zhigang Bai²  Zhongtao Zhang²  Alessandro Passardi³  Alessandro Bittoni³  Cornelis Sier⁴  Endrit Shahini⁵  Antonio Giovanni Solimando⁶ 

[1] Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resources Center, Soochow University, Suzhou, China;Department of General Surgery, Beijing Friendship Hospital, Capital Medical University and National Clinical Research Center for Digestive Diseases, Beijing, China;Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy;Department of Surgery, Leiden University Medical Center, Leiden, Netherlands;Gastroenterology Unit, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, Bari, Italy;Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J), University of Bari “A. Moro”, Bari, Italy;

关键词: angiogenesis;    gastrointestinal cancer;    ramucirumab;    anti-angiogenic therapies;    apatinib;   

DOI  :  10.3389/fonc.2023.1147849

 received in 2023-01-19, accepted in 2023-01-23,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Passardi, Bittoni, Bai, Zhang, Sier, He, Shahini and Solimando